Semaglutide 2.4 mg (Wegovy) is recommended by NICE (TA875) for eligible adults within specialist weight management services, and tirzepatide (Zepbound) has also received MHRA approval for weight management
Symptoms like rash, itching, swelling, dizziness, and trouble breathing mean you should see a doctor right away
Conclusions To summarize, the 68-week treatment with coadministered cagrilintide and semaglutide resulted in substantial and clinically meaningful weight loss in adults with overweight or obesity, significantly outperforming monotherapies and placebo (- 5.5% vs
Comprehensive staff training, coupled with a system of regular audits, forms a robust framework for ensuring consistent adherence to quality standards and minimizing errors
Very interesting
For best results, administer the injection in the upper arm, thigh, or buttocks using a clean, sterile syringe